Fri, Nov 28, 2014, 2:26 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Repligen Corporation Message Board

  • cddog1 cddog1 Dec 24, 2005 6:34 PM Flag

    As Those of us who have been

    here for years know there were two court battles with CTLAA4-ig which Rgen lost. They are:
    1. Original battle was lost.
    2. Appeal in Washington was lost.
    3. They did however recieve a new patent (a usage patent) after these two mentioned defeats.

    Now after having been exploded upon by someone whom I have never posted with nor know about the is protien A matter I will put one quick quote up here---The quote comes from page 8 of the 2001 Annual report as follows, "As the world's PRIMARY supplier of recombinant Protien A we expect to benefit from the continued growth in the market of antibodies."

    Now read this carefully it does not say that RGEN is the only supplier but the primary supplier. If this becomes very useful, as we assume, will RGEN continue to be "the primary supplier"? You can not say it will be nor can I say it will not be----but I do not appreciate the personal attack! If I had time I can produce other such creditable comments.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • hey Mr 2001 10k, this is a direct quote from the most recent form 10k filed-

      (Now eat shit and die you POS, illiterate piker!)

      Protein A



      We own a U.S. patent covering recombinant Protein A, which expires in 2009, as well as significant know-how in the manufacture of high-purity Protein A. We also own a U.S. patent covering modified forms of Protein A, which was non-exclusively licensed to Amersham Biosciences (now GE Healthcare) in 1998 as part of a ten year agreement, which was amended and expanded in 2005 until 2010, covering the supply of Protein A to GE Healthcare.



      In addition to its utility in antibody manufacture, Protein A may also be useful in human therapy based on its activity as a B-cell toxin. Repligen has exclusively licensed rights from the University of California, San Diego to a patent application which claims a variety of potential therapeutic uses of Protein A. Foreign equivalents of this patent application are also pending.

      • 1 Reply to baldingcontrarian
      • also for those of you who bothered to analyze the most recent CC at rodman / renshaw

        the Dr says essentially "our protein A is an embedded part of the manufacturing process of the drugs that utilize it, it would be difficult and expensive for them to be displaced."

        the Dr also clearly states "if Orencia is approved for an RA indication, ctla4Ig is approved we will seek to license our patent to them..."

        since you cant seem to do any due diligence and you cant seem to read i think we may have a problem with you-

 
RGEN
22.87-0.30(-1.29%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.